The treatment of type 2 diabetes mellitus often requires the use of one or more hypoglycemic
agents to reach the adequate glycemic control. The aim of the study is to evaluate the
effects of a triple therapy with metformin, pioglitazone and sitagliptin on glycemic
variability compared to metformin monotherapy, and compared to a combination of metformin and
pioglitazone. To assess glycemic variability a continuous glucose monitoring system will be
used.